Stem Cell and Derivatives

IWP-O1 is a highly potent Porcupine (Porcn) inhibitor (EC50: 80 pM), effectively suppresses the phosphorylation of Dvl2/3 and LRP6 in HeLa cells.

Ac-VDVAD-CHO is an inhibitor of caspase-2 and caspase-3 (IC50: 46 nM for caspase-2 and 15 nM for caspase-3) [1].

Dynarrestin inhibits cytoplasmic dynein 1/2, preventing microtubule sliding without affecting ATP hydrolysis or ciliogenesis.

Povorcitinib phosphate is a selective JAK1 inhibitor and can be used in studies about the treatment of cutaneous lupus erythematosus and Lichen planus.

SANT 2 is a Hedgehog (Hh) signaling pathway antagonist with potential anti-inflammatory and anti-cancer activities.

Wnt pathway inhibitor 3 is a potent AC1 inhibitor with an IC50 value of 45 nM.Wnt pathway inhibitor 3 has antiproliferative activity and can be used in studies

E2012 is a γ-secretase modulator (GSM).

AT13148 is an oral-active and ATP-competitive, multi-AGC kinase inhibitor for Akt1/2/3, p70S6K, PKA, and ROCKI/II.

NRX-103095 increases β-catenin binding to SCFβ-TrCP E3 ligase; EC50 is 163 nM for pSer33/Ser37 affinity boost.

IMR-1A is the metabolite of IMR-1 which is a novel class of Notch inhibitors targeting the transcriptional activation with IC50 of 6 μMol/L.

GSK-3β Inhibitor21 (compound 44) is an ATP-competitive inhibitor of GSK-3β with an IC50 value of 6.06 µM, characterized by its ability to inhibit tau phosphorylation and prevent amyloid protein aggregation. This compound is utilized in the research of Alzheimer's disease.

STAT3-IN-31 (compound K2071), derived from STATtic, acts as an inhibitor of both STAT3 and mitotic processes. This compound interrupts mitotic progression and impacts the formation of the mitotic spindle. Additionally, STAT3-IN-31 hampers migration in glioblastoma cells, suppresses cellular proliferation within tumor spheroids, induces senescence in glioblastoma, and inhibits the growth of Temozolomide-resistant cells while reducing the secretion of the pro-inflammatory cytokine monocyte chemoattractant protein (MCP-1).

JAK-IN-33 (Compound 3 (R)) is a selective inhibitor of the Janus kinase (JAK) family [1].

CDK8-IN-12: selective CDK8 inhibitor (Ki 14 nM), oral anticancer, blocks GSK-3α/β, PCK-θ, halts MV4-11 cell growth.

KY-05009 blocks TGF-β1 EMT in lung cancer cells, inhibits TNIK, Wnt genes, induces apoptosis, and is an ATP-competitive TNIK inhibitor (Ki = 100 nM).

Neocucurbitacin A (compound 7), a STAT3 inhibitor extracted from the pericarp of Aquilaria crassna, serves as a potential agent for anticancer research [1].

RGB-286638 free base inhibits CDKs (1-5 nM), weaker on CDK7/6.

Peficitinib (ASP015K) (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor. Phase 3.

LGK974 (NVP-LGK974) is a selective PORCN inhibitor that blocks Wnt signaling, used in metastatic colorectal and head/neck cancer trials. IC50: 0.4 nM.

FLLL32 is an effective JAK2/STAT3 inhibitor (IC50 of <5 μM).

AZD2858 is a selective GSK-3 inhibitor, inhibiting tau phosphorylation at the S396 site and activating Wnt signaling pathway.

RU-SKI 43: Potent, selective Hhat inhibitor, IC50 850 nM. Anticancer; potential lung adenocarcinoma treatment. Inhibits Gli-1, Akt, mTOR pathways.

Epiblastin A inhibits CK1, targets its isoenzymes, and converts EpiSCs to cESCs.

Cerdulatinib hydrochloride is an oral tyrosine kinase inhibitor targeting JAK1/2/3, TYK2, Syk, and 19 others with IC50 < 200 nM.

SMANT hydrochloride (N-(4-bromophenyl)-3-(3,5-dimethylpiperidin-1-yl)propanamide hydrochloride) is an antagonist of Smoothened accumulation.

Disitertide acetate: a TGF-β1 and PI3K blocker, promotes apoptosis; inhibits receptor interaction.

IWP-3 is a potent inhibitor of Wnt production with an IC50 of 40 nM. It inhibits Porcupine (Porcn), blocking the palmitoylation of Wnt proteins, and moderately inhibits CK1γ3 and CK1ε, but does not inhibit CK1α [1] [2].

GSK180736A: GRK2 inhibitor (IC50 0.77µM), >100x selectivity vs GRKs, weak at PKA (IC50 30µM), strong vs ROCK1 (IC50 100nM).

Tolnaftate (NP-27) is a synthetic antifungal agent.

MSC-4106, an oral YAP/TAZ-TEAD inhibitor, blocks TEAD1/3 auto-palmitoylation and suppresses NCI-H226 tumors.

Cerdulatinib (PRT2070) is an novel oral dual Syk/JAK inhibitor.

Tofacitinib Citrate (CP-690550 citrate) is a a potent, cell-permeable inhibitor of JAK1/2/3 (IC50s: 1/20/112 nM).

TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others

AR-A014418 (GSK 3β inhibitor VIII) is an ATP-competitive, and selective GSK3β inhibitor.

Aloisine B (AloisineB) inhibited cyclin-dependent kinase and glycogen synthase kinase with IC50 values of 0.85 µM and 0.75 µM, respectively.

Tubastatin inhibits TGF-β1-induced S6K phosphorylation, HIF-1α expression and VEG F expression.

Brevilin A, a sesquiterpene from Centipeda minima, hinders JAK and blocks STAT3 (IC50=10.6μM), inducing apoptosis and autophagy in cancer cells.

PIMPC, a compound endowed with antioxidant and metal-chelating properties, acts as a novel inhibitor of glycogen synthase kinase 3 (GSK-3), and exhibits

Rhodblock 6 is a Rho kinase inhibitor, blocking phosphorylated MRLC localization by targeting ROCK activity.

Wnt/β-catenin agonist 2 activates Wnt/β-catenin signaling and is an effective Wnt agonist.

Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable inhibitor of JAK2.

CUR61414 is a cell-permeable inhibitor of Hedgehog signaling pathway (IC50 =100-200 nM) and selectively binds to smoothened (Ki = 44 nM).

LSKL TFA (H-Leu-Ser-Lys-Leu-NH2 TFA) is a TGF-尾1 antagonist that inhibits TSP-1 binding to LAP and reduces renal interstitial fibrosis and liver fibrosis.

CCG 203769 (Thiadiazolidinone (TDZD) deriv. 6) is a selective inhibitor of RGS4 with an IC50 of 17 nM for the RGS4-Gαo protein-protein interaction.

DIF-3 activates GSK-3β, degrades cyclin D1/c-Myc, and inhibits Wnt/β-catenin in DLD-1 cells, curbing HeLa cell proliferation.

2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide (GDC046), a potent lead analog, has good kinase selectivity and physicochemical properties.

SAG 21k is an orally bioactive and potent Hedgehog signaling activator that crosses the blood-brain barrier for the study of cartilage regeneration.

BMP signaling agonist sb4 (SB 4) is an agonist of benzoxazole bone morphogenetic protein (BMP) signaling (EC50 :74 nM)

β-catenin modulator IIa-661 is a small molecule inhibitor of the Wnt pathway with antitumour activity.

JAK3-IN-6 is irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC50 of 0.15 nM

Cenacitinib is an effective inhibitor of Janus kinase (Janus kinase) and possesses anti-inflammatory activity.

JAK/HDAC-IN-2, a potent 2-amino-4-phenylaminopyrimidine dual-target inhibitor, effectively suppresses JAK1/2 and HDAC3/6 at nanomolar concentrations.

ARN25068 inhibits GSK-3β, FYN, DYRK1A kinases; acts in sub-micromolar range; combats tau hyperphosphorylation.

ELN318463 racemate (ELN 318463 racemate) is the racemate of ELN318463 which is an amyloid precursor protein (APP) selective γ-secretase inhibitor.

JAK2-IN-6: A potent JAK2-specific inhibitor (IC50=22.86μg/mL), blocks JAK2 signaling, has anticancer properties, and is inactive against JAK1/3.

SRI-011381, a new-type agonist of the TGF-beta signaling pathway, is utilized in the treatment of Alzheimer's disease.

Wnt pathway activator 1 is a potent Wnt activator with an IC50 of 28-29 nM.

Izencitinib (JNJ-8398) is a JAK inhibitor with potential anti-inflammatory activity for the study of ulcerative colitis and Crohn;s disease.

NSC 370284 inhibits STAT3/5, reducing AML cell viability with TET1 overexpression in vitro/in vivo.

JNJ-1289: potent hSMOX inhibitor, IC50 50 nM, potential for anticancer/anti-inflammatory research.

GKI-1 HCl is a Greatwall (GWL) kinase inhibitor that inhibits hGWLFL and hGWL-KinDom.The inhibitory effect of GKI-1 HCl on ROCK1 is more significant.

TBB (NSC-231634)(NSC-231634) is a highly selective, ATP/GTP-competitive inhibitor of casein kinase-2 (CK2).

The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Dog sCD14. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Dog sCD14. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Dog sCD14, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Dog sCD14 in the samples is then determined by comparing the OD of the samples to the standard curve.

pan-TEAD-IN-1 (Compound 3) is an orally active pan-inhibitor of TEAD, disrupting its interaction with coactivators YAP/TAZ by targeting the palmitoylation site of TEAD. This inhibition leads to the downregulation of oncogene transcription, such as Ctgf and Cyr61, within the Hippo signaling pathway. Demonstrating outstanding efficacy, pan-TEAD-IN-1 has an IC50 of 0.36 nM for luciferase and 1.52 nM for H226 cells, along with favorable pharmacokinetic properties (AUC0-∞= 228.7 μg/mL·min, T1/2= 183.9 min). The compound significantly inhibits tumor growth in xenograft models of TEAD-dependent cancers, indicating its potential for research in these cancer types.

IHR-1, a Smo inhibitor (IC50 7.6 nM), blocks Hedgehog pathway, not Wnt/Notch, and prevents Smo in primary cilium.